Extremely short telomeres and high telomerase activity in T-cell prolymphocytic leukemia (T-PLL): An optimal target for telomerase inhibition with GRN163L?

被引：2
|
作者：
Roeth, A.
de Beer, D.
Duerig, J.
Duehrsen, U.
Elias, L.
Tressler, R.
Baerlocher, G. M.
机构：
[1] Univ Hosp Essen, Essen, Germany
[2] Univ Bern, Bern, Switzerland
[3] Geron Corp, Menlo Pk, CA USA
[4] Univ Hosp Bern, CH-3010 Bern, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.7061
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7061
引用
收藏
页数：1
相关论文
共 48 条
  • [41] Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition
    Zhao, Yan-min
    Zhou, Qian
    Xu, Yun
    Lai, Xiao-yu
    Huang, He
    ACTA PHARMACOLOGICA SINICA, 2008, 29 (04) : 481 - 488
  • [42] Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition
    Yan-min Zhao
    Qian Zhou
    Yun Xu
    Xiao-yu Lai
    He Huang
    Acta Pharmacologica Sinica, 2008, 29 : 481 - 488
  • [43] Anti-leukemic activity through CDK9 inhibition in T-cell prolymphocytic leukemia
    Johansson, P.
    Dierichs, L.
    Klein-Hitpass, L.
    Bergmann, A.
    Menninger, S.
    Habenberger, P.
    Klebl, B.
    Siveke, J.
    Duehrsen, U.
    Choidas, A.
    Duerig, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 218 - 219
  • [44] JAK2 inhibition in JAK2V617F-bearing leukemia cells enriches CD34+ leukemic stem cells that are abolished by the telomerase inhibitor GRN163L
    Dahlstrom, Jenny
    Xia, Chuanyou
    Xing, Xiangling
    Yuan, Xiaotian
    Bjorkholm, Magnus
    Xu, Dawei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 527 (02) : 425 - 431
  • [45] Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation
    Gomez-Arteaga, Alexandra
    Margolskee, Elizabeth
    Wei, Mike T.
    van Besien, Koen
    Inghirami, Giorgio
    Horwitz, Steven
    LEUKEMIA & LYMPHOMA, 2019, 60 (07) : 1626 - 1631
  • [46] SEQUENTIAL THERAPY OF FLUDARABINE, MITOXANTRONE AND CYCLOPHOSPHAMIDE (FMC) INDUCTION FOLLOWED BY ALEMTUZUMAB CONSOLIDATION IS EFFECTIVE AND SAFE IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) - RESULTS FROM A MULTICENTER PHASE II TRIAL OF THE GERMAN CLL STUDY GROUP
    Hopfinger, G.
    Busch, R.
    Eichhorst, B.
    Westermann, A.
    Fink, A.
    Cramer, P.
    Weit, N.
    Pflug, N.
    Reinart, N.
    Winkler, D.
    Fingerle-Rowson, G.
    Stilgenbauer, S.
    Kandler, G.
    Doehner, H.
    Hallek, M.
    Herling, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 124 - 124
  • [47] T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients
    Damle, Rajendra N.
    Temburni, Sonal
    Banapour, Taraneh
    Paul, Santanu
    Mongini, Patricia K. A.
    Allen, Steven L.
    Kolitz, Jonathan E.
    Rai, Kanti R.
    Chiorazzi, Nicholas
    BLOOD, 2012, 120 (12) : 2438 - 2449
  • [48] Inhibition of telomerase activity and induction of apoptosis by Rhodospirillum rubrum L-asparaginase in cancer Jurkat cell line and normal human CD4+T lymphocytes
    Zhdanov, Dmitry D.
    Pokrovsky, Vadim S.
    Pokrovskaya, Marina V.
    Alexandrova, Svetlana S.
    Eldarov, Mikhail A.
    Grishin, Dmitry V.
    Basharov, Marsel M.
    Gladilina, Yulia A.
    Podobed, Olga V.
    Sokolov, Nikolai N.
    CANCER MEDICINE, 2017, 6 (11): : 2697 - 2712
12345